BTIG analyst Sean Lavin defended ABIOMED (NASDAQ: ABMD) saying buy on the STEMI weakness. Lavin reiterated a Buy rating and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE